retifanlimab,pembrolizumab,Bria-IMT
Incyte,Merck,BriaCell Therapeutics
['bria-imt']
briacell is presenting positive clinical data from its lead product candidate, bria-imt at the 2023 annual meeting. find more information here: #aacr2023 $bctx $bctxw 
An immuno-oncology company developing targeted and effective immunotherapies for advanced breast cancer and other cancers. (Nasdaq: $BCTX, $BCTXW) (TSX: BCT)